The Patient Who DefersThin moat
Intuitive Surgical (ISRG) — moat facet
More than half of these operations are benign, and a benign operation waits until the household can afford it.
The ultimate customer never appears in Intuitive's accounts, and 2026 was the year that mattered.
The relevant disclosure sits in the seasonality section of the 10-K, where it reads as an operational footnote: "More than half of da Vinci procedures performed are for benign conditions. These benign procedures and other short-term elective procedures tend to be more seasonal than cancer procedures and surgeries for other life-threatening conditions."1 The company adds that in the United States, benign volumes are "typically seasonally higher in the fourth quarter when more patients have met annual deductibles and lower in the first quarter when deductibles are reset."
Read that carefully and it says something larger than seasonality. A majority of the procedures generating Intuitive's recurring revenue are ones the patient can choose to postpone, and the thing they postpone them for is money.
In 2026 that mechanism ran at scale. Growth in deferrable benign categories — hernia repair, cholecystectomy — softened from the first quarter while non-deferrable categories did not2; United States da Vinci procedure growth fell from 14% to 12%3; and management cut full-year guidance to 13.5% to 15.5%4. Chief financial officer Jamie Samath's formulation was careful: the subsidy expiry "had a modest adverse impact on U.S. da Vinci procedure volume in Q2".
Note the word "impact" rather than loss. Management's position is that "the underlying disease burden has" not changed and the procedures will eventually be performed — deferral, not destruction. That is probably right, and it is also the argument every company makes about a demand air pocket while it is happening.
Intuitive's own response is the most telling evidence of how seriously it takes this. The Extended Use Program, announced on the same call, will raise the permitted number of uses on selected EndoWrist instruments in the first half of 2027, explicitly to "lower costs for benign procedures"5, and for the geographies where cost constraints are greatest. The company is cutting its own toll to keep the deferrable procedures happening.
The gap between deferrable and non-deferrable procedure growth is the thing to follow. Convergence means the deferral is unwinding. A persistent gap means the benign half of this business has a new and lower growth rate.
More than half of da Vinci procedures are elective and benign, and elective procedures are the first to wait when coverage tightens or a deductible resets. That sensitivity became visible in 2026 rather than theoretical.
Against 18% delivered in 2025 and 17% in 2024. The gap is deferral rather than displacement, which is why Intuitive keeps saying the disease burden has not changed.
Source: Intuitive Surgical Q2 2026 earnings call, July 16, 2026 ↗- ReportedThese benign procedures and other short-term elective procedures tend to be more seasonal than cancer procedures and surgeries for other life-threatening conditions." The company adds that in the United States, benign volumes are...Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 1 Business (the da Vinci and Ion platforms, instruments with a use count enforced in the instrument itself, training pathways and SimNow, enabling technologies, manufacturing sites, employees by function, and the seasonality of benign procedures) — FY2025 · publ. February 3, 2026 · source ↗
- ReportedGrowth in deferrable benign categories — hernia repair, cholecystectomy — softened from the first quarter while non-deferrable categories did not; United States da Vinci procedure growth fell from 14% to 12%; and management cut full-year...Intuitive Surgical Q2 2026 earnings call - the Extended Use Program raising permitted uses on selected EndoWrist instruments from the first half of 2027, US da Vinci procedure growth of 12% against 14% attributed to the expiry of enhanced Affordable Care Act premium subsidies, full-year guidance of 13.5% to 15.5% nearer the midpoint, gross-margin guidance raised to 68-69%, and Japanese placements of 25 against 15 — Q2 2026 · publ. July 16, 2026 · source ↗
- ReportedGrowth in deferrable benign categories — hernia repair, cholecystectomy — softened from the first quarter while non-deferrable categories did not; United States da Vinci procedure growth fell from 14% to 12%; and management cut full-year...Intuitive Surgical Q2 2026 earnings call - the Extended Use Program raising permitted uses on selected EndoWrist instruments from the first half of 2027, US da Vinci procedure growth of 12% against 14% attributed to the expiry of enhanced Affordable Care Act premium subsidies, full-year guidance of 13.5% to 15.5% nearer the midpoint, gross-margin guidance raised to 68-69%, and Japanese placements of 25 against 15 — Q2 2026 · publ. July 16, 2026 · source ↗
- ReportedGrowth in deferrable benign categories — hernia repair, cholecystectomy — softened from the first quarter while non-deferrable categories did not; United States da Vinci procedure growth fell from 14% to 12%; and management cut full-year...Intuitive Surgical Q2 2026 earnings call - the Extended Use Program raising permitted uses on selected EndoWrist instruments from the first half of 2027, US da Vinci procedure growth of 12% against 14% attributed to the expiry of enhanced Affordable Care Act premium subsidies, full-year guidance of 13.5% to 15.5% nearer the midpoint, gross-margin guidance raised to 68-69%, and Japanese placements of 25 against 15 — Q2 2026 · publ. July 16, 2026 · source ↗
- ReportedThe Extended Use Program, announced on the same call, will raise the permitted number of uses on selected EndoWrist instruments in the first half of 2027, specifically "to reduce customer costs in benign procedures and cost-constrained...Intuitive Surgical Q2 2026 earnings call - the Extended Use Program raising permitted uses on selected EndoWrist instruments from the first half of 2027, US da Vinci procedure growth of 12% against 14% attributed to the expiry of enhanced Affordable Care Act premium subsidies, full-year guidance of 13.5% to 15.5% nearer the midpoint, gross-margin guidance raised to 68-69%, and Japanese placements of 25 against 15 — Q2 2026 · publ. July 16, 2026 · source ↗
- Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 (SEC EDGAR)
- Intuitive Surgical Q2 2026 earnings call summary